

# Vitaliy Mykytiv

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7151234/publications.pdf>

Version: 2024-02-01

17  
papers

62  
citations

1684188

5  
h-index

1588992

8  
g-index

17  
all docs

17  
docs citations

17  
times ranked

108  
citing authors

#	ARTICLE	IF	CITATIONS
1	CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/TRIAL-IE 16-02 study. <i>Blood Advances</i> , 2019, 3, 1815-1825.	5.2	19
2	A panhaemocytometric approach to COVID-19: a retrospective study on the importance of monocyte and neutrophil population data on Sysmex XN-series analysers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e169-e172.	2.3	11
3	Anemia in patient with primary hyperoxaluria and bone marrow involvement by oxalate crystals. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 118-121.	0.9	9
4	Platelet hyperactivation in multiple myeloma is also evident in patients with premalignant monoclonal gammopathy of undetermined significance. <i>British Journal of Haematology</i> , 2021, 192, 322-332.	2.5	9
5	Double CD38 <sup>+</sup> /CD138 <sup>-</sup> negative multiple myeloma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2019, 12, 64-66.	0.9	8
6	The first case of acute myeloid leukaemia/myeloid sarcoma with cytokeratin expression on blasts diagnosed on urine specimen. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 343-347.	0.9	3
7	Repeat JAK2 V617F testing in patients with suspected essential thrombocythaemia. <i>Journal of Clinical Pathology</i> , 2020, 73, 772-772.	2.0	1
8	Minimal Residual Disease in Multiple Myeloma: Potential for Blood-Based Methods to Monitor Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e34-e40.	0.4	1
9	Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment. <i>Blood</i> , 2021, 138, 2756-2756.	1.4	1
10	Leukostasis as a result of rapidly progressive granulocytosis in a patient diagnosed with MDS/MPN-U. <i>Blood</i> , 2019, 134, 2117-2117.	1.4	0
11	A multicenter report on the natural history of myelodysplastic syndromes in very old patients (aged) Tj ETQq1 1 0.784314 rgBT /Over	1.3	0
12	Molecular responses in e19a2 BCR-ABL1 chronic myeloid leukemia. <i>Leukemia Research Reports</i> , 2020, 13, 100195.	0.4	0
13	Extramedullary pericardial haematopoiesis as a presenting feature of chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 194, 7-7.	2.5	0
14	Platelet hyperactivation and hyporesponsiveness at diagnosis in multiple myeloma persists during treatment initiation. <i>Thrombosis Research</i> , 2021, 203, 186-189.	1.7	0
15	Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older. <i>Blood</i> , 2018, 132, 5515-5515.	1.4	0
16	Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study. <i>Blood</i> , 2018, 132, 3242-3242.	1.4	0
17	Examining the Usefulness of the Charlson Comorbidity Index to Predict Early Mortality in Patients with Acute Myeloid Leukaemia. <i>Blood</i> , 2021, 138, 1218-1218.	1.4	0